



Genmab A/S

Carl Jacobsens Vej 30
2500 Valby
Denmark
Tel. +45 7020 2728
www.genmab.com
CVR no. 2102 3884

February 15, 2024

Dear Shareholder,

Please find enclosed an invitation to attend Genmab A/S' 2024 Annual General Meeting to be held on

Wednesday, March 13, 2024 at 14:00 PM CET at
Copenhagen Marriott Hotel
Kalvebod Brygge 5
1560 Copenhagen V
Denmark

Dear Shareholder,

For many years our team was a small one, but it was dedicated – dedicated to the idea that Genmab's innovations could someday make a difference in the lives of people with cancer. That someday is today. There are now eight approved medicines based on Genmab's innovation and antibody expertise, and our incredible team has grown to over 2,000 colleagues.

Epcoritamab became our second product on the market, approved as EPKINLY® in the U.S. and Japan and TEPKINLY® in Europe. With EPKINLY we are, for the first time in our history, the commercial lead in both the U.S. and Japan. We also saw very good progress with Tivdak® this year, with positive results from studies in cervical and head and neck cancers, and acasunlimab has also shown promise in second line non-small cell lung cancer. Our DuoBody partnership with Janssen Biotech, Inc. has continued to be fruitful.

As we successfully grew our promising portfolio and built our teams, the time came in 2023 to build a new, larger headquarters site in Copenhagen. This state-of-the-art building marks how far we've come as a company and houses 500 team members, all pulling together towards a common goal under the same roof. Our Global R&D Center also expanded with the opening of the Accelerator, an iconic multi-tenant building nestled in the heart of the Utrecht Science Park, now home to the efforts of many more of our antibody experts and scientists.

In addition to our core focus on antibody medicines for cancer, we are expanding our efforts as we grow into a fully integrated biotech. To this end in 2023 we partnered with argenx SE, giving us the opportunity to explore patients' needs in oncology as well as I&I.

Our success is only possible because of our talented and unstoppable team, the patients who participate in our clinical trials and their care partners, the investigators who run these trials, our partners who believe in the power of our cutting-edge technologies and antibody therapies, our supportive Board of Directors, and our shareholders who believe in our vision.

I look forward to elaborating on our progress at the Annual General Meeting. If you are unable to participate, I encourage you to return the enclosed proxy and I thank you for your continued support.

Sincerely yours,

A handwritten signature in blue ink, appearing to read "Jan van de Winkel", with a horizontal line extending to the right.

Jan van de Winkel, Ph.D.
President & Chief Executive Officer